Proteomics: New perspectives, new biomedical opportunities

Lancet

Volumn 356, Issue 9243, 2000, Pages 1749-1756

  Banks, Rosamonde E ^a   Dunn, Michael J ^b   Hochstrasser, Denis F ^c   Sanchez, Jean Charles ^c   Blackstock, Walter ^d   Pappin, Darryl J ^e   Selby, Peter J ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d GLAXOSMITHKLINE   (United Kingdom)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MESSENGER RNA; NEW DRUG; PRION PROTEIN; PROTEOME; VACCINE;

AGING; CANCER; CELL TYPE; CONFERENCE PAPER; DRUG DESIGN; DRUG RESEARCH; ENVIRONMENTAL FACTOR; GENETIC CODE; GENOME; HEART DISEASE; HUMAN; INFECTION; INFORMATION SCIENCE; MEDICAL RESEARCH; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING;

EID: 0034684425     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)03214-1     Document Type: Conference Paper

References (70)

1. Progress with gene-product mapping of the Mollicutes: Mycoplasma genitalium
2. Progress with proteome projects: Why all proteins expressed by a genome should be identified and how to do it
3. The human protein index
4. Biological function made crystal clear: Annotation of hypothetical proteins via structural genomics
5. Epigenesis: The missing beat in biotechnology
6. A comparison of selected mRNA and protein abundances in human liver
7. Current challenges and future applications for protein maps and post-translational vector maps in proteome projects
8. High resolution two-dimensional electrophoresis of proteins
9. The current state of two-dimensional electrophoresis with immobilized pH gradients
10. Melanie II: A third-generation software package for analysis of two-dimensional electrophoresis images - Features and user interface
11. Protein identification in the post-genome era: The rapid rise of proteomics
12. Electrospray ionization for mass spectrometry of large biomolecules
13. Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons
14. Proteome in perspective
15. Sharing of worldwide spread knowledge using hypermedia facilities and fast communication protocols (Mosaic and World Wide Web): The example of ExPASy
16. The SWISS-PROT protein sequence data bank and its supplement TrEMBL in 1998
17. Mass spectrometry and EST-database searching allows characterization of the multi-protein spliceosome complex
18. The yeast nuclear pore complex: Composition, architecture, and transport mechanism
19. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
20. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors
21. Proteome and proteomics: New technologies, new concepts, and new words
22. Genomic sciences and the medicine of tomorrow
23. Proteomics: Quantitative and physical mapping of cellular proteins
24. Cell biology and the genome projects: A concerted strategy for characterizing multiprotein complexes by using mass spectrometry
25. A protein expression database for the molecular pharmacology of cancer
26. The transcriptional program in the response of human fibroblasts to serum
27. A two-dimensional gel database of rat liver proteins useful in gene regulation and drug effects studies
28. New insights into cyclosporine A nephrotoxicity by proteome analysis
29. Abnormal proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
30. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease
31. 14-3-3 Protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease
32. New variant Creutzfeldt-Jakob disease: Neurological features and diagnostic tests
33. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples
34. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease
35. Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD
36. Reversion of prion protein conformational changes by synthetic b-sheet breaker peptides
37. Amyloid plaque core protein in Alzheimer disease and Down syndrome
38. Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein
39. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
40. The amyloid precursor protein of Alzheimer's disease and the Ab peptide
41. Review: Tau protein pathology in Alzheimer's disease and related disorders
42. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology
43. Proteomics in medical microbiology
44. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins
45. Recall of long-lived immunity to Mycobacterium tuberculosis infection in mice
46. Two-dimensional electrophoresis for analysis of Mycobacterium tuberculosis culture filtrate and purification and characterization of six novel proteins
47. New vaccines against tuberculosis: The status of current research
48. Delineation of human antibody responses to culture filtrate antigens of Mycobacterium tuberculosis
49. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M bovis
50. Cardiac protein abnormalities in dilated cardiomyopathy detected by two-dimensional polyacrylamide gel electrophoresis
51. Characterization of myocardial protein composition in dilated cardiomyopathy by two-dimensional gel electrophoresis
52. Dilated cardiomyopathy-associated proteins and their presentation in a WWW-accessible two-dimensional gel protein database
53. Bovine dilated cardiomyopathy: Proteomic analysis of an animal model of human dilated cardiomyopathy
54. Protein changes observed in pacing-induced heart failure using two-dimensional electrophoresis
55. Inappropriate ubiquitin conjugation: A proposed mechanism contributing to heart failure
56. Association of pretransplantation antiheart antibodies with clinical course after heart transplantation
57. Characterization of endothelial antigens associated with transplant-associated coronary artery disease
58. Cancer markers of the 1990s: Comparison of the new generation of markers defined by monoclonal antibodies and oncogene probes to prototypic markers
59. Simultaneous analysis of cyclin and oncogene expression using multiple monoclonal antibody immunoblots
60. Exploiting altered glycosylation patterns in cancer: Progress and challenges in diagnosis and therapy
61. Cancer proteomics: From identification of novel markers to creation of artificial learning models for tumor classification
62. Proteome profiling of bladder squamous cell carcinomas: Identification of markers that define their degree of differentiation
63. Proteomics and immunohistochemistry define some of the steps involved in the squamous differentiation of the bladder transitional epithelium: A novel strategy for identifying metaplastic lesions
64. The potential use of laser capture microdissection to selectively obtain distinct populations of cells for proteomic analysis: Preliminary findings
65. Laser capture microdissection
66. Protein arrays for gene expression and molecular interaction screening
67. A comprehensive analysis of protein-protein interactions in Saccharomyces cerevisiae
68. Strategies for selection of antibodies by phage display
69. Fingerprinting disease with protein chip arrays
70. A functional proteomics screen of proteases in colorectal carcinoma